Olaparib in Patients With HRD Malignant Mesothelioma
Public ClinicalTrials.gov record NCT04515836. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Trial of Olaparib in Homologous Recombination Deficient (HRD) Malignant Mesothelioma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
In this study, researchers will give olaparib (a drug) to mesothelioma patients who have specific changes in their DNA (known as gene mutations). Researchers will give this drug to each patient on the study to find out if it will help the patient's tumor shrink or stop growing.
Study identification
- NCT ID
- NCT04515836
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 56 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 18, 2021
- Primary completion
- Apr 14, 2028
- Completion
- Apr 14, 2028
- Last update posted
- May 5, 2025
2021 – 2028
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Chicago Medical Center | Chicago | Illinois | 60615 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Homologous Recombination Deficiency trials
Other public records listing Homologous Recombination Deficiency. Sorted by last update posted; newest first. Not a recommendation.
- NCT06545942: Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors Recruiting
- NCT07565155: Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency Not yet recruiting
- NCT04503265: A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies Recruiting
- NCT06525298: EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04515836, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 5, 2025 · Synced Jul 31, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04515836 live on ClinicalTrials.gov.